What is Brinter?
Founded in 2020 and headquartered in Turku, Finland, Brinter is a specialized bioprinting company that emerged from the Finnish 3D printing firm 3DTech Oy. Brinter offers comprehensive 3D bioprinting solutions and services tailored for the pharmaceutical, biotechnological, and cosmetic industries, as well as for universities and research facilities. The company's core offering includes custom-built bioprinters designed to meet the specific applications and needs of its clientele, positioning it as a key player in the rapidly evolving field of biofabrication.
How much funding has Brinter raised?
Brinter has raised a total of $1.4M across 1 funding round:
Angel/Seed
$1.4M
Angel/Seed (2021): $1.4M, investors not publicly disclosed
What's next for Brinter?
The recent major strategic investment signals a pivotal growth phase for Brinter. This capital infusion is expected to accelerate product development, enhance manufacturing capabilities, and expand market reach, particularly within the pharmaceutical and biotech sectors where precision bioprinting is critical for drug discovery and tissue engineering. Brinter's focus on custom solutions suggests a strategy aimed at capturing high-value contracts and fostering deep partnerships with research institutions and industry leaders. The company's trajectory indicates a move towards scaling its operations to meet increasing global demand for advanced bioprinting technologies.
See full Brinter company page
